Interpace Biosciences, Inc. (OTCMKTS:IDXG) Sees Large Decline in Short Interest

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the recipient of a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 306 shares, a decline of 61.0% from the June 15th total of 785 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 14,473 shares, the short-interest ratio is currently 0.0 days.

Interpace Biosciences Stock Performance

IDXG traded up $0.12 during trading on Wednesday, hitting $1.62. 800 shares of the stock were exchanged, compared to its average volume of 7,450. The firm has a 50 day simple moving average of $1.73 and a 200 day simple moving average of $1.72. The firm has a market cap of $7.18 million, a price-to-earnings ratio of -32.40 and a beta of 0.59. Interpace Biosciences has a 1 year low of $0.77 and a 1 year high of $2.40.

Interpace Biosciences (OTCMKTS:IDXG) last issued its earnings results on Tuesday, May 12th. The business services provider reported $0.03 earnings per share for the quarter. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.The business had revenue of $9.03 million during the quarter.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.